Events & Promotions
|
|
GMAT Club Daily Prep
Thank you for using the timer - this advanced tool can estimate your performance and suggest more practice questions. We have subscribed you to Daily Prep Questions via email.
Customized
for You
Track
Your Progress
Practice
Pays
Not interested in getting valuable practice questions and articles delivered to your email? No problem, unsubscribe here.
Nov 2007:30 AM PST
-08:30 AM PST
Learn what truly sets the UC Riverside MBA apart and how it helps in your professional growth
Nov 2211:00 AM IST
-01:00 PM IST
Do RC/MSR passages scare you? e-GMAT is conducting a masterclass to help you learn – Learn effective reading strategies Tackle difficult RC & MSR with confidence Excel in timed test environment- Nov 23
11:00 AM IST
-01:00 PM IST
Attend this free GMAT Algebra Webinar and learn how to master the most challenging Inequalities and Absolute Value problems with ease. 
Nov 2510:00 AM EST
-11:00 AM EST
Prefer video-based learning? The Target Test Prep OnDemand course is a one-of-a-kind video masterclass featuring 400 hours of lecture-style teaching by Scott Woodbury-Stewart, founder of Target Test Prep and one of the most accomplished GMAT instructors.
07 Feb 2025, 21:32
Kudos
Bookmarks
ᅠᅠA pharmaceutical company (hereafter, the company) developed Formula A, a prescription drug used to treat a common health condition. In the process of developing Formula A, the company also developed Formula B, a prescription drug derived from Formula A and used to treat the same condition.
ᅠᅠFor each prescription drug, the company was granted a 6-year exclusivity period'. a period of six years during which a company holds exclusive rights to produce and sell a drug that it has developed. The 6-year exclusivity period for Formula A spanned Years 1-6, while the 6-year exclusivity period for Formula B spanned Years 5-10.
ᅠᅠFor each prescription drug, the company was granted a 6-year exclusivity period'. a period of six years during which a company holds exclusive rights to produce and sell a drug that it has developed. The 6-year exclusivity period for Formula A spanned Years 1-6, while the 6-year exclusivity period for Formula B spanned Years 5-10.
Year 5
Be sure to select an answer first to save it in the Error Log before revealing the correct answer (OA)!
Difficulty:
5%
(low)
Question Stats:
88% (01:51) correct
12%
(01:41)
wrong
based on 602
sessions
History
Date
Time
Result
Not Attempted Yet
Based on the information provided, in which one of the following years were the company's combined revenues from sales of Formulas A and B the least?
| Year 5 | |
| Year 6 | |
| Year 7 | |
| Year 8 | |
| Year 9 |
ShowHide Answer
Official Answer
Year 5
Predicted revenue from sales of Formulas B and C for Year 11 is less than total R&D expenditures for Year 10.: Sufficient information
Predicted total revenue for Year 11 is greater than total revenue for Year 10.: Insufficient information
Predicted total R&D expenditures for Year 11 are less than total R&D expenditures for Year 10.: Insufficient information
Be sure to select an answer first to save it in the Error Log before revealing the correct answer (OA)!
Difficulty:
75%
(hard)
Question Stats:
53% (01:55) correct
47%
(01:57)
wrong
based on 765
sessions
History
Date
Time
Result
Not Attempted Yet
The company has been granted a 6-year exclusivity period, spanning Years 11-16, for Formula C, a new drug designed to treat a different condition than that treated by Formulas A and B. The company has made the following predictions for Year 11: revenue from sales of Formula B will be US$400 million, and revenue from sales of Formula C will be US$200 million.
For each of the following statements about the company, select Sufficient information if the given predictions and the information in the tabs provide sufficient information to determine that the statement is true. Otherwise, select Insufficient information.
For each of the following statements about the company, select Sufficient information if the given predictions and the information in the tabs provide sufficient information to determine that the statement is true. Otherwise, select Insufficient information.
| Sufficient information | Insufficient information | |
| Predicted revenue from sales of Formulas B and C for Year 11 is less than total R&D expenditures for Year 10. | ||
| Predicted total revenue for Year 11 is greater than total revenue for Year 10. | ||
| Predicted total R&D expenditures for Year 11 are less than total R&D expenditures for Year 10. |
ShowHide Answer
Official Answer
Predicted revenue from sales of Formulas B and C for Year 11 is less than total R&D expenditures for Year 10.: Sufficient information
Predicted total revenue for Year 11 is greater than total revenue for Year 10.: Insufficient information
Predicted total R&D expenditures for Year 11 are less than total R&D expenditures for Year 10.: Insufficient information
The company's total R&D expenditures were greater than those for any other year of the6-year exclusively period for Formula A.: No
The company's total R&D expenditures were greater than 10% of the company's total revenue.: No
Revenue from sales of Formula A accounted for more than 50% of the company's total revenue.: No
Be sure to select an answer first to save it in the Error Log before revealing the correct answer (OA)!
Difficulty:
85%
(hard)
Question Stats:
50% (02:00) correct
50%
(02:16)
wrong
based on 775
sessions
History
Date
Time
Result
Not Attempted Yet
For each of the following statements about the final year of the 6-year exclusivity period for Formula A, select Yes if the statement is supported by the information in the tabs. Otherwise, select No.
| Yes | No | |
| The company's total R&D expenditures were greater than those for any other year of the6-year exclusively period for Formula A. | ||
| The company's total R&D expenditures were greater than 10% of the company's total revenue. | ||
| Revenue from sales of Formula A accounted for more than 50% of the company's total revenue. |
ShowHide Answer
Official Answer
The company's total R&D expenditures were greater than those for any other year of the6-year exclusively period for Formula A.: No
The company's total R&D expenditures were greater than 10% of the company's total revenue.: No
Revenue from sales of Formula A accounted for more than 50% of the company's total revenue.: No
Attachment:
2024-08-23_19-06-01.png [ 97.47 KiB | Viewed 7792 times ]
Attachment:
2024-08-23_19-03-17.png [ 101.23 KiB | Viewed 7801 times ]
poojaarora1818
Joined: 30 Jul 2019
Last visit: 19 Nov 2025
Posts: 1,543
Given Kudos: 3,423
Location: India
Concentration: General Management, Economics
Schools: Duke '26 Haas '26 Kelley '26 Kellogg '26 McDonough '26
GPA: 3
WE:Human Resources (Human Resources)
Products:
08 Feb 2025, 03:50
Kudos
Bookmarks
Bismuth83
Ques 1 The company has been granted a 6-year exclusivity period, spanning Years 11-16, for Formula C, a new drug designed to treat a different condition than that treated by Formulas A and B. The company has made the following predictions for Year 11: revenue from sales of Formula B will be US$400 million, and revenue from sales of Formula C will be US$200 million.
For each of the following statements about the company, select Sufficient information if the given predictions and the information in the tabs provide sufficient information to determine that the statement is true. Otherwise, select Insufficient information.
Solution: Combining all the revenues from Formulas A & B sales. The year that shows the least is Year 5.
Ques 2 The company has been granted a 6-year exclusivity period, spanning Years 11-16, for Formula C, a new drug designed to treat a different condition than that treated by Formulas A and B. The company has made the following predictions for Year 11: revenue from sales of Formula B will be US$400 million, and revenue from sales of Formula C will be US$200 million.
For each of the following statements about the company, select Sufficient information if the given predictions and the information in the tabs provide sufficient information to determine that the statement is true. Otherwise, select Insufficient information.
Solution 1) Sufficient --As mentioned in the ques the total revenue from sales of Formula B will be US$400 million and revenue from sales of Formula C will be US$200 million for the year 11. So, when we combine both we get $600 which is less than the t[color=#000000]otal R&D expenditures for Year 10 which is $800.
2) Insufficient-- We only have the predicted revenue for year 11 from the sales of Formula B and Formula C and also we do not have enough information about the revenue for year 10. And, Year 10 only speaks about Formula A & B. So, it is insufficient.
3)Insufficient-- We do not have enough information about the R & D expenditure for the year 11. Not enough data to make such predictions.
Ques 3. For each of the following statements about the final year of the 6-year exclusivity period for Formula A, select Yes if the statement is supported by the information in the tabs. Otherwise, select No.
1) No-- The company's total R&D expenditures were greater than those for any other year of the 6-year exclusive period for Formula A.
2) No-- The company's total R&D expenditures were greater than 10% of the company's total revenue.
3) No-- Revenue from sales of Formula A accounted for more than 50% of the company's total revenue. [/color]
13 Feb 2025, 07:14
Kudos
Bookmarks
Why 'NO" in all of last question "For each of the following statements about the final year of the 6-year exclusivity period for Formula A, select Yes if the statement is supported by the information in the tabs. Otherwise, select No." ?
All information was provided.
All information was provided.
